JP5579057B2 - 再発性癌の処置のための方法および組成物 - Google Patents

再発性癌の処置のための方法および組成物 Download PDF

Info

Publication number
JP5579057B2
JP5579057B2 JP2010510376A JP2010510376A JP5579057B2 JP 5579057 B2 JP5579057 B2 JP 5579057B2 JP 2010510376 A JP2010510376 A JP 2010510376A JP 2010510376 A JP2010510376 A JP 2010510376A JP 5579057 B2 JP5579057 B2 JP 5579057B2
Authority
JP
Japan
Prior art keywords
cancer
certain embodiments
composition
taxane
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010510376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529025A5 (Direct
JP2010529025A (ja
Inventor
ニール ピー． デサイ，
パトリック スーン−シオン，
Original Assignee
アブラクシス バイオサイエンス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブラクシス バイオサイエンス， エルエルシー filed Critical アブラクシス バイオサイエンス， エルエルシー
Publication of JP2010529025A publication Critical patent/JP2010529025A/ja
Publication of JP2010529025A5 publication Critical patent/JP2010529025A5/ja
Application granted granted Critical
Publication of JP5579057B2 publication Critical patent/JP5579057B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010510376A 2007-06-01 2008-06-02 再発性癌の処置のための方法および組成物 Active JP5579057B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93275007P 2007-06-01 2007-06-01
US60/932,750 2007-06-01
PCT/US2008/007024 WO2008150532A1 (en) 2007-06-01 2008-06-02 Methods and compositions for treating recurrent cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014140474A Division JP2014185186A (ja) 2007-06-01 2014-07-08 再発性癌の処置のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2010529025A JP2010529025A (ja) 2010-08-26
JP2010529025A5 JP2010529025A5 (Direct) 2011-07-14
JP5579057B2 true JP5579057B2 (ja) 2014-08-27

Family

ID=39733105

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010510376A Active JP5579057B2 (ja) 2007-06-01 2008-06-02 再発性癌の処置のための方法および組成物
JP2014140474A Pending JP2014185186A (ja) 2007-06-01 2014-07-08 再発性癌の処置のための方法および組成物
JP2016134757A Pending JP2016172777A (ja) 2007-06-01 2016-07-07 再発性癌の処置のための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014140474A Pending JP2014185186A (ja) 2007-06-01 2014-07-08 再発性癌の処置のための方法および組成物
JP2016134757A Pending JP2016172777A (ja) 2007-06-01 2016-07-07 再発性癌の処置のための方法および組成物

Country Status (11)

Country Link
US (3) US8927019B2 (Direct)
EP (1) EP2155188B1 (Direct)
JP (3) JP5579057B2 (Direct)
AU (1) AU2008260447B2 (Direct)
CA (1) CA2689914C (Direct)
DK (1) DK2155188T3 (Direct)
ES (1) ES2435452T3 (Direct)
HR (1) HRP20131142T1 (Direct)
PL (1) PL2155188T3 (Direct)
PT (1) PT2155188E (Direct)
WO (1) WO2008150532A1 (Direct)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
MX383644B (es) 2005-02-18 2025-03-14 Abraxis Bioscience Llc Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
EP2117520B1 (en) 2006-12-14 2018-08-29 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
EP2131821B1 (en) 2007-03-07 2018-05-09 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
CA2686736A1 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension
DK2155188T3 (da) 2007-06-01 2013-11-04 Abraxis Bioscience Llc Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
EP3626233A1 (en) 2009-04-15 2020-03-25 Abraxis BioScience, LLC Prion-free nanoparticle compositions and methods
NZ598801A (en) * 2009-09-18 2014-07-25 Abraxis Bioscience Llc Use of the sparc microenvironment signature in the treatment of cancer
ES2580135T3 (es) 2010-03-26 2016-08-19 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
KR101894689B1 (ko) 2010-03-29 2018-09-04 아브락시스 바이오사이언스, 엘엘씨 암의 치료 방법
KR20180050426A (ko) 2010-03-29 2018-05-14 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
CA2801190A1 (en) 2010-06-03 2011-12-08 Abraxis Bioscience, Llc Use of the sparc microenvironment signature in the treatment of cancer
CA2801645A1 (en) 2010-06-04 2011-12-08 Abraxis Bioscience, Llc Use of nanoparticules comprising a taxane and an albumin in the treatment of pancreatic cancer
CN103648521A (zh) 2011-04-28 2014-03-19 阿布拉科斯生物科学有限公司 纳米颗粒组合物的血管内递送及其应用
KR20140107417A (ko) 2011-12-14 2014-09-04 아브락시스 바이오사이언스, 엘엘씨 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도
SG10201914117QA (en) * 2012-05-09 2020-02-27 Cantex Pharmaceuticals Inc Treatment Of Myelosuppression
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
WO2014159171A1 (en) 2013-03-12 2014-10-02 Abraxis Bioscience, Llc Methods of treating lung cancer
WO2017161387A1 (en) * 2016-03-18 2017-09-21 Reid Christopher Brian Compositions of natural extracts and use thereof in methods for preventing or treating diseases
SG11201507234UA (en) 2013-03-14 2015-10-29 Abraxis Bioscience Llc Methods of treating bladder cancer
WO2016089873A1 (en) 2014-12-02 2016-06-09 Celgene Corporation Combination therapies
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
HUE070408T2 (hu) 2015-06-29 2025-06-28 Abraxis Bioscience Llc Szirolimuszt és albumint tartalmazó nanorészecskék epitelioid sejtes tumorok kezelésében történõ alkalmazásra
CN119139479A (zh) 2015-09-16 2024-12-17 Dfb索里亚有限责任公司 包含紫杉烷类纳米颗粒的组合物及其用途
CN105412024B (zh) 2015-12-14 2018-03-30 广州帝奇医药技术有限公司 靶向疏水性抗肿瘤药物纳米制剂及其制备方法
CN108697637A (zh) * 2016-01-27 2018-10-23 因斯塔尔科技股份公司 用于治疗性处理的口腔粘膜纳米纤维载体
US11585805B2 (en) 2016-02-19 2023-02-21 Nantcell, Inc. Methods of immunogenic modulation
US11406684B2 (en) 2016-08-26 2022-08-09 Tetsuji Okuno Fine nano-sized medicinal agent and use thereof
EP3595633B1 (en) 2017-03-15 2023-07-05 DFB Soria, LLC Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
CN112165949A (zh) 2018-03-16 2021-01-01 Dfb索里亚有限责任公司 使用紫杉烷纳米颗粒治疗宫颈上皮内瘤变(cin)和宫颈癌的局部疗法
AU2019239953B2 (en) 2018-03-20 2025-01-02 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
KR20220106758A (ko) 2019-10-28 2022-07-29 아브락시스 바이오사이언스, 엘엘씨 알부민 및 라파마이신의 제약 조성물
WO2023070023A1 (en) * 2021-10-21 2023-04-27 Faeth Therapeutics, Inc. Combination therapy for pik3ca-associated diseases or disorders

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
IT1197485B (it) * 1986-10-07 1988-11-30 Boehringer Biochemia Srl Composizioni farmaceutiche ad attivita' antineoplastica
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US20070117863A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5997904A (en) 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
ES2219646T5 (es) * 1993-02-22 2008-11-01 Abraxis Bioscience, Inc. Metodos para la administracion in vivo de compuestos biologicos y composiciones utiles para los mismos.
US20030068362A1 (en) 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6528067B1 (en) * 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
EP1683517A1 (en) 1996-08-19 2006-07-26 American Bioscience, Inc. Methods for the production of protein particles useful for delivery of pharmacological agents
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
IL132094A0 (en) * 1997-03-27 2001-03-19 Baker Norton Pharma Methods and compositions for treatment of ovarian cancer
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
KR100789008B1 (ko) 1997-06-27 2007-12-26 아브락시스 바이오사이언스 인크. 신규 약물 제제
EP1171117A4 (en) 1999-04-22 2002-08-07 American Bioscience Inc LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS
EP1178786A4 (en) 1999-05-21 2006-03-01 American Bioscience Inc PHARMACOLOGICALLY ACTIVE PROTEIN STABILIZING AGENTS; METHODS OF MANUFACTURE AND METHODS OF USE
ITMI20001107A1 (it) 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
ATE406892T1 (de) 2001-04-06 2008-09-15 Wyeth Corp Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
CA2480809A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
US20040126400A1 (en) * 2002-05-03 2004-07-01 Iversen Patrick L. Delivery of therapeutic compounds via microparticles or microbubbles
WO2004052401A2 (en) 2002-12-09 2004-06-24 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
SI1585548T1 (sl) * 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
AU2003293529A1 (en) * 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US20050038498A1 (en) * 2003-04-17 2005-02-17 Nanosys, Inc. Medical device applications of nanostructured surfaces
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
EP1755653B1 (en) 2004-05-14 2014-12-31 Abraxis BioScience, LLC Treatment methods utilizing albumin-binding proteins as targets
CN101060831B (zh) * 2004-10-01 2010-06-23 拉姆斯科股份有限公司 可方便植入的缓释药物组合物
WO2006053754A1 (en) 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
MX383644B (es) * 2005-02-18 2025-03-14 Abraxis Bioscience Llc Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
CN101146514B (zh) 2005-02-18 2013-03-27 阿布拉西斯生物科学公司 用于整合入医疗装置的疏水性改善的药物
BRPI0606282A2 (pt) * 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições injetáveis de compostos imunossupressores em nanopartìculas
US7514549B2 (en) * 2005-04-16 2009-04-07 Michigan State University Tumor inhibition by modulating sprouty expression or activity
EP1888062A1 (en) 2005-05-16 2008-02-20 Novartis AG The use of rapamycin derivatives for the treatment and/or prevention of cardiovascular disorders
BRPI0615265A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
JP5368093B2 (ja) * 2005-08-31 2013-12-18 アブラクシス バイオサイエンス， エルエルシー 増大した安定性を有する難水溶性薬剤の組成物および調製の方法
US20080280987A1 (en) 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
AU2006347740A1 (en) 2006-08-31 2008-03-06 Abraxis Bioscience, Llc Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20100112077A1 (en) * 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
ITFI20060277A1 (it) * 2006-11-08 2008-05-09 Giuliano Giustini Sollevatore per motociclette e simili, offrente mobilita' di spostamenti omnidirezionali
EP2117520B1 (en) 2006-12-14 2018-08-29 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
EP2131821B1 (en) 2007-03-07 2018-05-09 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
CA2686736A1 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension
DK2155188T3 (da) 2007-06-01 2013-11-04 Abraxis Bioscience Llc Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
US20120128732A1 (en) * 2008-12-11 2012-05-24 Vuong Trieu Combinations and modes of administration of therapeutic agents and combination therapy
JP5725563B2 (ja) * 2009-03-13 2015-05-27 アブラクシス バイオサイエンス， エルエルシー チオコルヒチン誘導体との組み合わせ療法
MX2011010673A (es) * 2009-04-10 2012-02-21 Abraxis Bioscience Llc Formulaciones de nanoparticulas y usos de las mismas.
EP3626233A1 (en) 2009-04-15 2020-03-25 Abraxis BioScience, LLC Prion-free nanoparticle compositions and methods
DK2470173T3 (en) * 2009-08-25 2016-06-06 Abraxis Bioscience Llc Combination therapy of nanoparticle composition of the taxane and the hedgehog inhibitors
US9775819B2 (en) * 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
US8269348B2 (en) * 2010-02-22 2012-09-18 Texas Instruments Incorporated IC die including RDL capture pads with notch having bonding connectors or its UBM pad over the notch
ES2580135T3 (es) * 2010-03-26 2016-08-19 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
KR101894689B1 (ko) * 2010-03-29 2018-09-04 아브락시스 바이오사이언스, 엘엘씨 암의 치료 방법
KR20180050426A (ko) * 2010-03-29 2018-05-14 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
ES2639038T3 (es) * 2010-06-02 2017-10-25 Abraxis Bioscience, Llc Métodos para el tratamiento de cáncer de vejiga
CA2801645A1 (en) * 2010-06-04 2011-12-08 Abraxis Bioscience, Llc Use of nanoparticules comprising a taxane and an albumin in the treatment of pancreatic cancer
RU2016103126A (ru) * 2010-06-07 2018-11-22 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы комбинированной терапии для лечения пролиферативных заболеваний
US8871256B2 (en) * 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US9149455B2 (en) * 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US20140186447A1 (en) * 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US9511046B2 (en) * 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
US20140199404A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras

Also Published As

Publication number Publication date
US20150079181A1 (en) 2015-03-19
JP2016172777A (ja) 2016-09-29
HK1140944A1 (en) 2010-10-29
PL2155188T3 (pl) 2014-03-31
JP2014185186A (ja) 2014-10-02
CA2689914A1 (en) 2008-12-11
PT2155188E (pt) 2013-12-19
US20140017316A1 (en) 2014-01-16
AU2008260447B2 (en) 2013-10-10
AU2008260447A1 (en) 2008-12-11
CA2689914C (en) 2016-08-16
ES2435452T3 (es) 2013-12-19
WO2008150532A1 (en) 2008-12-11
US20160158365A9 (en) 2016-06-09
EP2155188B1 (en) 2013-10-09
US8927019B2 (en) 2015-01-06
EP2155188A1 (en) 2010-02-24
JP2010529025A (ja) 2010-08-26
HRP20131142T1 (hr) 2014-01-03
DK2155188T3 (da) 2013-11-04
US20100215751A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
JP5579057B2 (ja) 再発性癌の処置のための方法および組成物
AU2018200347B2 (en) Methods of treatment of pancreatic cancer
EP2968254B1 (en) Methods of treating lung cancer
AU2014228386B2 (en) Methods of treatment of pediatric solid tumor
JP2019085422A (ja) がんを処置する方法
JP2013527232A (ja) 膀胱がんの処置方法
CN109730998A (zh) 米铂白蛋白纳米粒组合物及其制法
HK1140944B (en) Methods and compositions for treating recurrent cancer
AU2013203373B2 (en) Methods of treating lung cancer
HK1220110B (en) Methods of treating lung cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130419

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130529

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140404

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140609

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140708

R150 Certificate of patent or registration of utility model

Ref document number: 5579057

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250